Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
Low testosterone is one label laid across two entirely different failures
Benefits (Research Focus) Triple receptor agonism studied for simultaneous activation of GLP-1, GIP, and glucagon receptors Body composition research investigated for fat-mass and lean-mass partitioning in DIO rodent models Glycemic endpoints examined for fasting glucose and HbA1c parameters in T2D research models Energy expenditure explored for glucagon-mediated thermogenic effects unique among incretin analogs Long-acting profile C20 fatty diacid albumin-binding chemistry for extended half-life research What Researchers Look At Receptor binding affinity and selectivity across GLP-1R / GIPR / GCGR cAMP activation curves in cell lines expressing each receptor subtype Food intake, body weight, and adipose-tissue change in DIO rodent models Hepatic steatosis, ALT/AST, and liver fat fraction endpoints Comparative pharmacology versus semaglutide, tirzepatide, and other incretin analogs Quick Specs Form: Lyophilized white powder Net Peptide Content: 10 mg per vial Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound: Retatrutide Synonyms: LY3437943
Clinical implication Although the association between GLP-1 RAs and gallbladder/biliary diseases has been supported by multiple studies, causality has not been definitively established
Full appetite has returned
Lowers risk of heart failure and stroke The protective effects of GLP-1 medications translate into impressive reductions in serious cardiovascular events
US$ 20.47
US$ 22.90
US$ 29.31
